Shopping Cart 0
Cart Subtotal
AED 0

MediGene AG (MDG1) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Single User License
AED 918

Restricted to one authorized user; Open on 1 PC/ mobile / Tablet only.
Print Option: Yes
Copy Option: No
Deliverable Format : PDF Via Email

Site License
AED 1835

Multiple Users within the Company/ Enterprise
Print Option: Yes
Copy Option: Yes
Deliverable Format : Excel, PDF Via Email

Corporate User License
AED 2753

Details

Summary

MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects and kills tumor cells and T-cell-specific monoclonal antibodies (TAB's), helps to remove unwanted T cells from the body. MediGene also has one marketed drug, Veregen for the treatment of genital warts. The company has operational presence in US, Europe and Asia. Medigene is headquartered in Martinsried, Germany.

MediGene AG (MDG1)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Table Of Content

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

MediGene AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

MediGene AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

MediGene AG, Pharmaceuticals & Healthcare, Deal Details 13

Private Equity 13

Cowen Healthcare Royalty Acquires Royalties Of Eligard From Medigene For USD 18 Million 13

Partnerships 14

Structured Immunity and Medigene Enter into Research Agreement 14

MediGene Enters into Research Agreement with RXi Pharma 15

Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 16

Medigene Enters into Agreement with University of Lausanne 17

PharmaDerm and MediGene Enter into Agreement with Women's Choice Pharma 18

Medigene Enters Into Co Marketing Agreement With Kora Healthcare For Veregen 19

Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 20

Medigene Enters Into Co-Marketing Agreement With Nordic For Veregen, Genital Warts Drug 21

MediGene Enters Into Co-Development Agreement For EndoTAG-1 22

MediGene Enters Into Co-Marketing Agreement With Azanta For Veregen 23

Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 24

Licensing Agreements 25

2A Pharma Enters into Licensing Agreement with MediGene 25

MediGene Expands Licensing Agreement with bluebird bio 26

Medigene Enters Into Licensing Agreement With Dr. Falk Pharma 27

Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 28

Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 29

MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 30

MediGene Enters Into Licensing Agreement With Eczacibasi Ilac Pazarlama For Veregen 31

Medigene Enters Into Licensing Agreement With Difa Cooper For Veregen 32

MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 33

Equity Offering 34

Medigene Raises USD37.9 Million in Private Placement of Shares 34

Medigene to Raise USD18.8 Million in Private Placement of Shares 35

Medigene Raises USD22.6 Million in Private Placement of Shares 37

Medigene Raises USD52 Million in Rights Offering of Shares 38

Medigene Raises USD20.3 Million in Rights Offering of Securities 40

Asset Transactions 41

Fougera Pharma Acquires US Rights to Veregen from Medigene 41

SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 42

Acquisition 43

Tongyang Networks Acquires 29.72% Stake in MediGene for USD28 Million 43

Medigene Sells Minority Stake in Immunocore 44

Amgen to Acquire Catherex from Medigene 45

Medigene Acquires Trianta Immunotherapies 46

MediGene AG-Key Competitors 47

MediGene AG-Key Employees 48

MediGene AG-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Recent Developments 50

Financial Announcements 50

May 09, 2018: Medigene reports First Quarter 2018 financials and provides operational update 50

Mar 22, 2018: Medigene publishes 2017 annual report 52

Nov 09, 2017: Medigene Reports Nine Months' Results 2017 55

Aug 03, 2017: Medigene Reports Results of First Six Months 2017 57

May 11, 2017: Medigene Reports Results Of First Quarter 2017 58

Mar 23, 2017: Medigene publishes its 2016 annual report and outlook for 2017 60

Corporate Communications 62

Sep 03, 2018: Medi gene an nounces change in ex ec ut ive lead er ship team 62

Apr 11, 2018: Medigene appoints Dr. Kai Pinkernell to the Executive Management Board as CMO/CDO 63

Aug 08, 2017: Medigene announces formation of new Scientific Advisory Board 64

May 11, 2017: Dave Lemus Steps Down As COO And Continues Cooperation In An Advisory Role 65

Product News 66

08/30/2017: Medigene Presents Automated Platform For Tcr Identification At Car-Tcr Summit 66

08/28/2017: Medigene presents approaches for improving selection of neoantigens for use in cancer immunotherapy 67

08/25/2017: Medigene Announces Participation At Five Upcoming Scientific And Investor Conferences 69

08/16/2017: Medigene Presents Posters on Immunotherapies at CRI-CIMT-EATI-AACR Conference 70

06/08/2017: Medigene and Academic Partners Publish a Method to Enhance Adoptive T-cell Therapies 71

04/04/2017: Academic Partner Presented Compassionate Use Data On AML DC Vaccine At AACR Conference 72

03/23/2017: Medigene: Announces target and outlines design for its first clinical trial in TCR cancer immunotherapy 73

Appendix 74

Methodology 74

About GlobalData 74

Contact Us 74

Disclaimer 74


List Of Figure

List of Figures

MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10


List Of Table

List of Tables

MediGene AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

MediGene AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

MediGene AG, Deals By Therapy Area, 2012 to YTD 2018 10

MediGene AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cowen Healthcare Royalty Acquires Royalties Of Eligard From Medigene For USD 18 Million 13

Structured Immunity and Medigene Enter into Research Agreement 14

MediGene Enters into Research Agreement with RXi Pharma 15

Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 16

Medigene Enters into Agreement with University of Lausanne 17

PharmaDerm and MediGene Enter into Agreement with Women's Choice Pharma 18

Medigene Enters Into Co Marketing Agreement With Kora Healthcare For Veregen 19

Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 20

Medigene Enters Into Co-Marketing Agreement With Nordic For Veregen, Genital Warts Drug 21

MediGene Enters Into Co-Development Agreement For EndoTAG-1 22

MediGene Enters Into Co-Marketing Agreement With Azanta For Veregen 23

Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 24

2A Pharma Enters into Licensing Agreement with MediGene 25

MediGene Expands Licensing Agreement with bluebird bio 26

Medigene Enters Into Licensing Agreement With Dr. Falk Pharma 27

Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 28

Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 29

MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 30

MediGene Enters Into Licensing Agreement With Eczacibasi Ilac Pazarlama For Veregen 31

Medigene Enters Into Licensing Agreement With Difa Cooper For Veregen 32

MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 33

Medigene Raises USD37.9 Million in Private Placement of Shares 34

Medigene to Raise USD18.8 Million in Private Placement of Shares 35

Medigene Raises USD22.6 Million in Private Placement of Shares 37

Medigene Raises USD52 Million in Rights Offering of Shares 38

Medigene Raises USD20.3 Million in Rights Offering of Securities 40

Fougera Pharma Acquires US Rights to Veregen from Medigene 41

SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 42

Tongyang Networks Acquires 29.72% Stake in MediGene for USD28 Million 43

Medigene Sells Minority Stake in Immunocore 44

Amgen to Acquire Catherex from Medigene 45

Medigene Acquires Trianta Immunotherapies 46

MediGene AG, Key Competitors 47

MediGene AG, Key Employees 48

MediGene AG, Subsidiaries 49

Licence Rights

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Section Purchase

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products and Companies

Products

MediGene AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.

Company Profile

Company Profile Title

Summary

MediGene AG (MediGene) is a biotechnology company which develops drugs for the treatment of various types and stages of cancer with candidates in clinical and pre-clinical development. The company focuses on the development of personalized T-cell-based immunotherapies. Its core business develops three immunotherapy platforms including DC vaccines to kill tumor cells; T-cell receptor (TCR) detects and kills tumor cells and T-cell-specific monoclonal antibodies (TAB's), helps to remove unwanted T cells from the body. MediGene also has one marketed drug, Veregen for the treatment of genital warts. The company has operational presence in US, Europe and Asia. Medigene is headquartered in Martinsried, Germany.

MediGene AG (MDG1)-Pharmaceuticals & Healthcare-Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals-Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.

- Deals by Year-Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.

- Deals by Type-Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.

- Deals by Region-Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.

- Deals by Sub-sector-Chart and table showing information on the number of deals and value reported by the company, by sub-sector.

- Major Deals-Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company's (major public companies) key financial metrics and ratios.

- Business Description-A brief description of the company's operations.

- Key Employees-A list of the key executives of the company.

- Important Locations and Subsidiaries-A list and contact details of key centers of operation and subsidiaries of the company.

- Key Competitors-A list of the key competitors of the company.

- Key Recent Developments-A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements

- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy

- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company

- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company's operations to identify potential customers and suppliers.

- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company

- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research

- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.

READ MORE

Scope

Table of Contents

Table of Contents 3

List of Tables 5

List of Figures 5

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

MediGene AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10

MediGene AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

MediGene AG, Pharmaceuticals & Healthcare, Deal Details 13

Private Equity 13

Cowen Healthcare Royalty Acquires Royalties Of Eligard From Medigene For USD 18 Million 13

Partnerships 14

Structured Immunity and Medigene Enter into Research Agreement 14

MediGene Enters into Research Agreement with RXi Pharma 15

Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 16

Medigene Enters into Agreement with University of Lausanne 17

PharmaDerm and MediGene Enter into Agreement with Women's Choice Pharma 18

Medigene Enters Into Co Marketing Agreement With Kora Healthcare For Veregen 19

Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 20

Medigene Enters Into Co-Marketing Agreement With Nordic For Veregen, Genital Warts Drug 21

MediGene Enters Into Co-Development Agreement For EndoTAG-1 22

MediGene Enters Into Co-Marketing Agreement With Azanta For Veregen 23

Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 24

Licensing Agreements 25

2A Pharma Enters into Licensing Agreement with MediGene 25

MediGene Expands Licensing Agreement with bluebird bio 26

Medigene Enters Into Licensing Agreement With Dr. Falk Pharma 27

Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 28

Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 29

MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 30

MediGene Enters Into Licensing Agreement With Eczacibasi Ilac Pazarlama For Veregen 31

Medigene Enters Into Licensing Agreement With Difa Cooper For Veregen 32

MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 33

Equity Offering 34

Medigene Raises USD37.9 Million in Private Placement of Shares 34

Medigene to Raise USD18.8 Million in Private Placement of Shares 35

Medigene Raises USD22.6 Million in Private Placement of Shares 37

Medigene Raises USD52 Million in Rights Offering of Shares 38

Medigene Raises USD20.3 Million in Rights Offering of Securities 40

Asset Transactions 41

Fougera Pharma Acquires US Rights to Veregen from Medigene 41

SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 42

Acquisition 43

Tongyang Networks Acquires 29.72% Stake in MediGene for USD28 Million 43

Medigene Sells Minority Stake in Immunocore 44

Amgen to Acquire Catherex from Medigene 45

Medigene Acquires Trianta Immunotherapies 46

MediGene AG-Key Competitors 47

MediGene AG-Key Employees 48

MediGene AG-Locations And Subsidiaries 49

Head Office 49

Other Locations & Subsidiaries 49

Recent Developments 50

Financial Announcements 50

May 09, 2018: Medigene reports First Quarter 2018 financials and provides operational update 50

Mar 22, 2018: Medigene publishes 2017 annual report 52

Nov 09, 2017: Medigene Reports Nine Months' Results 2017 55

Aug 03, 2017: Medigene Reports Results of First Six Months 2017 57

May 11, 2017: Medigene Reports Results Of First Quarter 2017 58

Mar 23, 2017: Medigene publishes its 2016 annual report and outlook for 2017 60

Corporate Communications 62

Sep 03, 2018: Medi gene an nounces change in ex ec ut ive lead er ship team 62

Apr 11, 2018: Medigene appoints Dr. Kai Pinkernell to the Executive Management Board as CMO/CDO 63

Aug 08, 2017: Medigene announces formation of new Scientific Advisory Board 64

May 11, 2017: Dave Lemus Steps Down As COO And Continues Cooperation In An Advisory Role 65

Product News 66

08/30/2017: Medigene Presents Automated Platform For Tcr Identification At Car-Tcr Summit 66

08/28/2017: Medigene presents approaches for improving selection of neoantigens for use in cancer immunotherapy 67

08/25/2017: Medigene Announces Participation At Five Upcoming Scientific And Investor Conferences 69

08/16/2017: Medigene Presents Posters on Immunotherapies at CRI-CIMT-EATI-AACR Conference 70

06/08/2017: Medigene and Academic Partners Publish a Method to Enhance Adoptive T-cell Therapies 71

04/04/2017: Academic Partner Presented Compassionate Use Data On AML DC Vaccine At AACR Conference 72

03/23/2017: Medigene: Announces target and outlines design for its first clinical trial in TCR cancer immunotherapy 73

Appendix 74

Methodology 74

About GlobalData 74

Contact Us 74

Disclaimer 74


List Of Figure

List of Figures

MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2

MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2

MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

MediGene AG, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8

MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

MediGene AG, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10


List Of Table

List of Tables

MediGene AG, Pharmaceuticals & Healthcare, Key Facts, 2017 2

MediGene AG, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7

MediGene AG, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8

MediGene AG, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9

MediGene AG, Deals By Therapy Area, 2012 to YTD 2018 10

MediGene AG, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 11

Cowen Healthcare Royalty Acquires Royalties Of Eligard From Medigene For USD 18 Million 13

Structured Immunity and Medigene Enter into Research Agreement 14

MediGene Enters into Research Agreement with RXi Pharma 15

Medigene Enters into Agreement with Max Delbruck Center for Molecular Medicine and Charite- Universitatsmedizin Berlin 16

Medigene Enters into Agreement with University of Lausanne 17

PharmaDerm and MediGene Enter into Agreement with Women's Choice Pharma 18

Medigene Enters Into Co Marketing Agreement With Kora Healthcare For Veregen 19

Medigene Enters Into Co-Marketing Agreement With Taurus Pharma For Veregen 20

Medigene Enters Into Co-Marketing Agreement With Nordic For Veregen, Genital Warts Drug 21

MediGene Enters Into Co-Development Agreement For EndoTAG-1 22

MediGene Enters Into Co-Marketing Agreement With Azanta For Veregen 23

Medigene Enters Into Co-Marketing Agreement With Bial For Veregen 24

2A Pharma Enters into Licensing Agreement with MediGene 25

MediGene Expands Licensing Agreement with bluebird bio 26

Medigene Enters Into Licensing Agreement With Dr. Falk Pharma 27

Medigene Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Center 28

Trianta Immunotherapies Enters into Licensing Agreement with Helmholtz Zentrum Munchen and Max Delbruck Centre for Molecular Medicine Berlin-Buch 29

MediGene Enters Into Licensing Agreement With SynCore Biotechnology For EndoTAG-1 30

MediGene Enters Into Licensing Agreement With Eczacibasi Ilac Pazarlama For Veregen 31

Medigene Enters Into Licensing Agreement With Difa Cooper For Veregen 32

MediGene Expands Licensing Agreement With Syncore Biotech For Veregen 33

Medigene Raises USD37.9 Million in Private Placement of Shares 34

Medigene to Raise USD18.8 Million in Private Placement of Shares 35

Medigene Raises USD22.6 Million in Private Placement of Shares 37

Medigene Raises USD52 Million in Rights Offering of Shares 38

Medigene Raises USD20.3 Million in Rights Offering of Securities 40

Fougera Pharma Acquires US Rights to Veregen from Medigene 41

SynCore Biotech to Acquire Rights to EndoTAG-1 from MediGene 42

Tongyang Networks Acquires 29.72% Stake in MediGene for USD28 Million 43

Medigene Sells Minority Stake in Immunocore 44

Amgen to Acquire Catherex from Medigene 45

Medigene Acquires Trianta Immunotherapies 46

MediGene AG, Key Competitors 47

MediGene AG, Key Employees 48

MediGene AG, Subsidiaries 49

Single User License:
Report can be used by individual purchaser only

Site License:
Report can be shared by unlimited users within one corporate location, e.g. a regional office

Corporate User License: 
Report can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

To know more information on Purchase by Section, please send a mail to support@kenresearch.com

INQUIRE FOR COVID-19 IMPACT ANALYSIS

Products

MediGene AG, Deal Analysis, Mergers, Acquisitions, Asset Purchases, Asset Divestitures, Company Divestitures, Equity Offerings, Capital Raising, Debt Offerings, IPOs, Initial Public Offering, Private Placement, Private Investment In Public Equities, Secondary Offerings, Follow-On Offerings, Debt Private Placement, Public Debt Placement, Partnerships, Joint Venture, Licensing Agreements, Co-Marketing Agreements, Upfront Payment, Milestone Payment, Phases, Clinical Trials, Private Equity, Venture Capital, PE,VC, Asset Finance, Project Finance, Tax Equity Financing, Bond Financing, Lease Financing, New Build Financing, Deal Analysis By Market/sector, Deal Analysis By Geography, Deal Analysis By Deal Types, Key Employees, Locations And Subsidiaries, Competitors, Recent News, Company Overview, Key Facts, Deals By Year, Deal Details, Recent Developments, Significant Developments.